The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prediction of Survival by [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial
Open accessAbstract
Purpose: In this prospective National Cancer Institute–funded American College of Radiology Imaging Network/Radiation Therapy Oncology Group cooperative group trial, we hypothesized that standardized uptake value (SUV) on post-treatment [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) correlates with survival in stage III non–small-cell lung cancer (NSCLC). Patients and Methods: Patients received conventional concurrent platinum-based chemoradiotherapy without surgery; postradiotherapy consolidation chemotherapy was allowed. Post-treatment FDG-PET was performed at approximately 14 weeks after radiotherapy. SUVs were analyzed both as peak SUV (SUV peak) and maximum SUV (SUV max; both institutional and central review readings), with institutional SUV peak as the primary end point. Relationships between the continuous and categorical (cutoff) SUVs and survival were analyzed using Cox proportional hazards multivariate models. Results: Of 250 enrolled patients (226 were evaluable for pretreatment SUV), 173 patients were evaluable for post-treatment SUV analyses. The 2-year survival rate for the entire population was 42.5%. Pretreatment SUV peak and SUV max (mean, 10.3 and 13.1, respectively) were not associated with survival. Mean post-treatment SUV peak and SUV max were 3.2 and 4.0, respectively. Post-treatment SUV peak was associated with survival in a continuous variable model (hazard ratio, 1.087; 95% CI, 1.014 to 1.166; P = .020). When analyzed as a prespecified binary value (≤ v > 3.5), there was no association with survival. However, in exploratory analyses, significant results for survival were found using an SUV peak cutoff of 5.0 (P = .041) or 7.0 (P < .001). All results were similar when SUV max was used in univariate and multivariate models in place of SUV peak. Conclusion: Higher post-treatment tumor SUV (SUV peak or SUV max) is associated with worse survival in stage III NSCLC, although a clear cutoff value for routine clinical use as a prognostic factor is uncertain at this time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impact of the Definition of Peak Standardized Uptake Value on Quantification of Treatment Response
Vanderhoek, M., Perlman, S. B., & Jeraj, R. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.093443 · Cited by 188
Cited by
Clinical development of new drug–radiotherapy combinations
on behalf of the NCRI CTRad Academia-Pharma Joint Working Group, Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.79 · Cited by 320
ibex: An open infrastructure software platform to facilitate collaborative work in radiomics
Zhang, L., Fried, D. V., Fave, X. J., Hunter, L. A., Yang, J., & Court, L. E. (2015) · Medical Physics · doi:10.1118/1.4908210 · Cited by 316
PET in the management of locally advanced and metastatic NSCLC
Grootjans, W., de Geus-Oei, L.-F., Troost, E. G. C., Visser, E. P., Oyen, W. J. G., & Bussink, J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.75 · Cited by 97
Developing biomarker-specific end points in lung cancer clinical trials
Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.222 · Cited by 51
Dosani, M., Yang, R., McLay, M., Wilson, D., Liu, M., Yong-Hing, C. J., Hamm, J., Lund, C. R., Olson, R., & Schellenberg, D. (2019) · Current Oncology · doi:10.3747/co.26.4167 · Cited by 28
Metadata
- Authors
- Machtay, M., Duan, F., Siegel, B. A., Snyder, B. S., Gorelick, J. J., Reddin, J. S., Munden, R., Johnson, D. W., Wilf, L. H., DeNittis, A., Sherwin, N., Cho, K. H., Kim, S.-K., Videtic, G., Neumann, D. R., Komaki, R., Macapinlac, H., Bradley, J. D., & Alavi, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-10-20
- Volume
- 31
- Issue
- 30
- Pages
- 3823-3830
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123507044
- Cited by
- 175
- References
- 1
- FWCI
- 16.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.